{"data":{"Year":[2000,2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015,2016,2017,2018,2019,2020,2020,2015,2016,2017,2018,2019,2020,2011,2012,2013,2014,2015,2016,2017,2018,2019,2020],"SDG Series":["Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to affordable medicines and vaccines on a sustainable basis, human papillomavirus (HPV) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]"],"Value":[82,80,84,73,73,76,80,81,88,88,90,96,94,87,92,89,89,82,92,91,89,16,28,32,35,45,49,49,85,82,75,81,75,78,82,92,91,90]},"edges":[]}